(Sharecast News) - Cell engineering company MaxCyte announced the appointment of Ali Soleymannezhad as its new chief commercial officer on Thursday, effective from 11 September.
The AIM-traded firm said in the role, Soleymannezhad would oversee its commercial operations, aiming to drive greater adoption of the 'ExPERT' platform, provide top-tier scientific, technical, and regulatory support to customers, and expand its market influence in the cell and gene therapy sectors.
Soleymannezhad would bring 20 years of experience in technical sales, marketing, and product development to his new position.
Before becoming executive vice-president of bioprocessing at MaxCyte, he held the role of executive vice-president for the separations and purification business at Tosoh Bioscience, managing a team of 140 employees across four global manufacturing, development, and commercial sites.
He also served as vice-president of global marketing and business development, director of sales and marketing for the Americas at Tosoh, and was a board member of Semba Biosciences.
"I am delighted to promote Ali to the role of chief commercial officer," said president and chief executive officer Maher Masoud.
"His diverse experience, skills, and leadership at MaxCyte as executive vice-president of bioprocessing have strengthened our organisation's product development and commercial strategies.
"We look forward to working alongside Ali as he leads our commercial efforts to drive future growth at MaxCyte."
At 1115 BST, shares in MaxCyte were up 0.71% at 285p.
Reporting by Josh White for Sharecast.com.
MaxCyte (MXCT)
